PFSA vs DBVT vs DXCM vs ALKS

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 26. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 26.

8x versus DexCom, Inc. at 29. 3x.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +70.

6%, compared to -99. 8% for Profusa, Inc. Common Stock (PFSA). Over 10 years, the gap is even starker: DXCM returned +299. 9% versus PFSA's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DexCom, Inc.

(DXCM) is the lower-risk stock at 0. 92β versus Profusa, Inc. Common Stock's 2. 99β — meaning PFSA is approximately 224% more volatile than DXCM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 51% for DexCom, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: DexCom, Inc. grew EPS 47. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DexCom, Inc.

(DXCM) is the more profitable company, earning 17. 9% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 17. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

7% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DexCom, Inc.

(DXCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), +299. 9% 10Y return). Profusa, Inc. Common Stock (PFSA) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DXCM: +299. 9%, PFSA: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PFSA is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; DXCM is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.